carvedilol   Click here for help

GtoPdb Ligand ID: 551

Synonyms: Coreg® | DQ 2466 | Eucardic® | SKF 105517
Approved drug
carvedilol is an approved drug (FDA (1995))
Compound class: Synthetic organic
Comment: Carvedilol is a non-selective β blocker
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 2
Hydrogen bond donors 3
Rotatable bonds 10
Topological polar surface area 75.74
Molecular weight 406.19
XLogP 3.76
No. Lipinski's rules broken 0

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

SMILES / InChI / InChIKey
Click here for help
Canonical SMILES COc1ccccc1OCCNCC(COc1cccc2c1c1ccccc1[nH]2)O
Isomeric SMILES COc1ccccc1OCCNCC(COc1cccc2c1c1ccccc1[nH]2)O
InChI InChI=1S/C24H26N2O4/c1-28-21-10-4-5-11-22(21)29-14-13-25-15-17(27)16-30-23-12-6-9-20-24(23)18-7-2-3-8-19(18)26-20/h2-12,17,25-27H,13-16H2,1H3
InChI Key OGHNVEJMJSYVRP-UHFFFAOYSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

References
1. Baker JG. (2005)
Evidence for a secondary state of the human beta3-adrenoceptor.
Mol Pharmacol, 68 (6): 1645-55. [PMID:16129733]
2. Baker JG. (2005)
Site of action of beta-ligands at the human beta1-adrenoceptor.
J Pharmacol Exp Ther, 313 (3): 1163-71. [PMID:15716385]
3. Baker JG. (2005)
The selectivity of beta-adrenoceptor antagonists at the human beta1, beta2 and beta3 adrenoceptors.
Br J Pharmacol, 144 (3): 317-22. [PMID:15655528]
4. Baker JG. (2026)
Comparing the Molecular Pharmacological Properties of Existing β-Blockers to Determine the Theoretically Most "Ideal" Anti-Cancer β-Blocker.
Pharmacol Res Perspect, 14 (1): e70214. [PMID:41485077]
5. Baker JG, Gardiner SM, Woolard J, Fromont C, Jadhav GP, Mistry SN, Thompson KSJ, Kellam B, Hill SJ, Fischer PM. (2017)
Novel selective β1-adrenoceptor antagonists for concomitant cardiovascular and respiratory disease.
FASEB J, 31 (7): 3150-3166. [PMID:28400472]
6. Baker JG, Hall IP, Hill SJ. (2003)
Agonist actions of "beta-blockers" provide evidence for two agonist activation sites or conformations of the human beta1-adrenoceptor.
Mol Pharmacol, 63 (6): 1312-21. [PMID:12761341]
7. Baker JG, Hall IP, Hill SJ. (2003)
Agonist and inverse agonist actions of beta-blockers at the human beta 2-adrenoceptor provide evidence for agonist-directed signaling.
Mol Pharmacol, 64 (6): 1357-69. [PMID:14645666]
8. Baker JG, Kemp P, March J, Fretwell L, Hill SJ, Gardiner SM. (2011)
Predicting in vivo cardiovascular properties of β-blockers from cellular assays: a quantitative comparison of cellular and cardiovascular pharmacological responses.
FASEB J, 25 (12): 4486-97. [PMID:21865315]
9. Baker JG, Proudman RG, Hill SJ. (2013)
Impact of polymorphic variants on the molecular pharmacology of the two-agonist conformations of the human β1-adrenoceptor.
PLoS One, 8 (11): e77582. [PMID:24250787]
10. Baker JG, Proudman RG, Hill SJ. (2014)
Identification of key residues in transmembrane 4 responsible for the secondary, low-affinity conformation of the human β1-adrenoceptor.
Mol Pharmacol, 85 (5): 811-29. [PMID:24608857]
11. Baker JG, Proudman RG, Hill SJ. (2015)
Salmeterol's extreme β2 selectivity is due to residues in both extracellular loops and transmembrane domains.
Mol Pharmacol, 87 (1): 103-20. [PMID:25324048]
12. Candelore MR, Deng L, Tota L, Guan XM, Amend A, Liu Y, Newbold R, Cascieri MA, Weber AE. (1999)
Potent and selective human beta(3)-adrenergic receptor antagonists.
J Pharmacol Exp Ther, 290 (2): 649-55. [PMID:10411574]
13. Proudman RGW, Baker JG. (2025)
A Comparison of the Molecular Pharmacological Properties of Current Short, Long, and Ultra-Long-Acting β2-Agonists Used for Asthma and COPD.
Pharmacol Res Perspect, 13 (5): e70154. [PMID:40887869]
14. Proudman RGW, Pupo AS, Baker JG. (2020)
The affinity and selectivity of α-adrenoceptor antagonists, antidepressants, and antipsychotics for the human α1A, α1B, and α1D-adrenoceptors.
Pharmacol Res Perspect, 8 (4): e00602. [PMID:32608144]
15. Smith C, Teitler M. (1999)
Beta-blocker selectivity at cloned human beta 1- and beta 2-adrenergic receptors.
Cardiovasc Drugs Ther, 13 (2): 123-6. [PMID:10372227]
16. Smith CD, Wang A, Vembaiyan K, Zhang J, Xie C, Zhou Q, Wu G, Chen SR, Back TG. (2013)
Novel carvedilol analogues that suppress store-overload-induced Ca2+ release.
J Med Chem, 56 (21): 8626-55. [PMID:24124794]